iSpecimen Inc. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 10 rows, 10 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-06-21: Reporting owner Ross Andrew L.; Form 4; Security Series A Preferred Stock; Transaction C Conversion of derivative security.
- 2021-06-21: Reporting owner Ross Andrew L.; Form 4; Security Series B Preferred Stock; Transaction C Conversion of derivative security.
- 2021-06-21: Reporting owner Mullan Jill; Form 4; Security Series A Preferred Stock; Transaction C Conversion of derivative security.
- 2021-06-21: Reporting owner Ianelli Christopher; Form 4; Security Series A Preferred Stock; Transaction C Conversion of derivative security.
ISPC insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-06-21 | Ross Andrew L. Director, 10% Owner | 4 | Series A Preferred Stock Derivative · Direct · (m) | C Conversion of derivative security | −355,005 0 owned after | no price filed | $5,792.00 | 2021-06-23 |
| 2021-06-21 | Ross Andrew L. Director, 10% Owner | 4 | Series B Preferred Stock Derivative · Direct · (m) | C Conversion of derivative security | −130,081 0 owned after | no price filed | $5,792.00 | 2021-06-23 |
| 2021-06-21 | Mullan Jill Director, Officer (COO, Secretary, Treasurer) | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −6,250 0 owned after | no price filed | $5,792.00 | 2021-06-23 |
| 2021-06-21 | Ianelli Christopher Director, Officer (CEO, President) | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −2,663 0 owned after | no price filed | $5,792.00 | 2021-06-23 |
| 2021-06-21 | OBF Investments, LLC | Scholl George H. 10% Owner | Director, 10% Owner | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −250,456 0 owned after | no price filed | $5,792.00 | 2021-06-23 |
| 2021-06-17 holding as of filing | OBF Investments, LLC | Scholl George H. 10% Owner | Director | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2021-06-17 | ||
| 2021-06-17 holding as of filing | Mullan Jill Director, Officer (COO, Secretary, Treasurer) | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2021-06-17 | ||
| 2021-06-17 holding as of filing | Ross Andrew L. Director, 10% Owner | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2021-06-17 | ||
| 2021-06-17 holding as of filing | Ross Andrew L. Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2021-06-17 | ||
| 2021-06-17 holding as of filing | Ianelli Christopher Director, Officer (CEO, President) | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2021-06-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |